Literature DB >> 19101258

Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation.

Fengshi Chen1, Mitsugu Omasa, Nobuyuki Kondo, Takuji Fujinaga, Tsuyoshi Shoji, Hiroaki Sakai, Toru Bando.   

Abstract

Pulmonary lymphangioleiomyomatosis is a rare disease that generally progresses to respiratory failure. We experienced a patient who had recurring lymphangioleiomyomatosis in the transplanted lungs. A chest computed tomographic scan showed a progressing emphysematous change. The patient had a subclinical extent of pan-circumferential stricture at the distal site of the left bronchial anastomosis. We treated the patient with sirolimus for three years. Chest computed tomography showed no sign of exacerbation during the late 3 years, whereas pulmonary function test revealed a slight increase after the use of sirolimus. Bronchial stricture also disappeared almost completely. This is the first reported case with sirolimus treatment for post-transplant recurrent lymphangioleiomyomatosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19101258     DOI: 10.1016/j.athoracsur.2008.07.107

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.

Authors:  Bruno Guedes Baldi; Marcos Naoyuki Samano; Silvia Vidal Campos; Martina Rodrigues de Oliveira; José Eduardo Afonso Junior; Rafael Medeiros Carraro; Ricardo Henrique Oliveira Braga Teixeira; Isabela Pasqualini Minguini; Roni Burlina; Eduardo Zinoni Silva Pato; Carlos Roberto Ribeiro Carvalho; André Nathan Costa
Journal:  Lung       Date:  2017-08-19       Impact factor: 2.584

2.  "Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies.

Authors:  Jonathan S Bleeker; J Fernando Quevedo; Andrew L Folpe
Journal:  Sarcoma       Date:  2012-04-26

3.  Successful management of bilateral refractory chylothorax after double lung transplantation for lymphangioleiomyomatosis.

Authors:  Mohammed Hussein; Yasser M Aljehani; Imran Nizami; Waleed Saleh
Journal:  Ann Thorac Med       Date:  2014-04       Impact factor: 2.219

4.  Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.

Authors:  Xiangke Li; Xiaolei Liu; Linda Zhang; Chenggang Li; Erik Zhang; Wang Ma; Qingxia Fan; Jane J Yu
Journal:  Oncotarget       Date:  2017-05-30

5.  Lung Transplantation for Lymphangioleiomyomatosis in Japan.

Authors:  Katsutoshi Ando; Yoshinori Okada; Miki Akiba; Takashi Kondo; Tomohiro Kawamura; Meinoshin Okumura; Fengshi Chen; Hiroshi Date; Takeshi Shiraishi; Akinori Iwasaki; Naoya Yamasaki; Takeshi Nagayasu; Masayuki Chida; Yoshikazu Inoue; Toyohiro Hirai; Kuniaki Seyama; Michiaki Mishima
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.